No Data
Zhejiang Tianyu Pharmaceutical (300702.SZ): Changyi Tianyu has successfully passed the recognition as a high-tech enterprise for the first time.
On March 4th, Gllonghui reported that Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that its wholly-owned subsidiary Changyi Tianyu Pharmaceutical Co., Ltd. (referred to as "Changyi Tianyu") recently received the "High-tech Enterprise Certificate" jointly issued by the Shandong Provincial Science and Technology Department, Shandong Provincial Finance Department, and the State Taxation Administration of Shandong Provincial Taxation Bureau.
Zhejiang Tianyu Pharmaceutical (300702.SZ) passed the on-site inspection by the FDA in the USA.
Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that the company will be...
Tianyu Pharmaceutical Unit's Edoxaban Tosylate Passes Chinese Drug Administration's Review
Zhejiang Tianyu Pharmaceutical (300702.SZ): The Active Pharmaceutical Ingredient of Maleic Acid Avapritinib has passed the CDE review.
Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that the Active Pharmaceutical Ingredient for Malatopar is recently approved by the National Medical Products Administration...
Zhejiang Tianyu Pharmaceutical (300702.SZ) announced an earnings increase, expecting an annual net income of 50 million to 75 million yuan, a year-on-year growth of 82.75% to 174.13%.
Zhejiang Tianyu Pharmaceutical (300702.SZ) disclosed the performance forecast for the year 2024, and the company expects to attribute its performance to the Shareholders of the listed company...
Tianyu Co., Ltd.: 2024 Annual Results Forecast
Further Weakness as Zhejiang Tianyu Pharmaceutical (SZSE:300702) Drops 11% This Week, Taking Three-year Losses to 64%
